logo
  

Novartis Names Merck Executive Strigini As Oncology Business Head

Swiss drug giant Novartis AG (NVS) said Sunday that it has appointed a senior executive of Merck & Co. (MRK), Bruno Strigini, as president of its oncology business, Novartis Oncology. His appointment is with immediate effect.

Novartis said in mid-January that Herve Hoppenot resigned as president of Novartis Oncology to pursue a career opportunity outside of the organization. At that time, the company appointed Alessandro Riva as president of Novartis Oncology on an interim basis, until a successor was found for Hoppenot who has led the oncology business since 2010.

Strigini most recently served as president for Merck's Europe/Canada operations, a region comprising 37 countries with over 10,000 associates. He has 25 years of experience in pharmaceuticals, animal health, OTC and vaccines, having led in both international and local roles.

During his career, Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham.

Strigini is a member of the Executive Committee for the European Federation of
Pharmaceutical Industries & Associations or EFPIA, as well as a member of the
Academie Nationale de Pharmacie in France.

Novartis said in April that it agreed to acquire the oncology business of GlaxoSmithKline plc (GSK, GSK.L) for $14.5 billion and up to $1.5 billion contingent milestone. The company also said it will divest Vaccines, excluding flu, to GSK, for $7.1 billion. The deal with GSK is expected to close during the first half of 2015.

In a separate statement, Novartis said that data from a pivotal mid-stage study of its investigational compound LDE225 showed marked tumor responses in advanced basal cell carcinoma. The company revealed the data at the 50th Annual Meeting of the American Society of Clinical Oncology or ASCO in Chicago.

According to Novartis, the Phase II study met the primary endpoint with objective response rates of 41.8 percent and 32.5 percent respectively in the 200 mg and 800 mg treatment arms. Basal cell carcinoma is the most common form of skin cancer and can be highly disfiguring at advanced stages and life-threatening when metastatic.

NVS closed Friday's trading at $90.06, down $0.10 or 0.11 percent on a volume of 4.09 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting its financial results for the second quarter on Thursday, Kellogg Co. (K) reaffirmed its currency-neutral adjusted earnings growth guidance for the full year 2021. For fiscal 2021, the company now projects currency-neutral adjusted earnings per share growth of about 1 to 2 percent... Moderna Inc. (MRNA) reported a profit for the second quarter compared to a loss in the previous year, reflecting surging revenues on commercial sales of the company's COVID-19 vaccine in the U.S. Quarterly earnings per share and revenues topped analysts' expectations. The company raised its 2021 sales forecast for its COVID-19 vaccine. New Widetech has recalled dehumidifiers sold under various brand names citing fire and burn risks, the U.S. Consumer Product Safety Commission said. The brand names include AeonAir, Amana, Haier, Honeywell, and Whirlpool, among others. The recall was initiated after New Widetech received reports of 107 incidents of the recalled dehumidifiers overheating and/or catching fire.
Follow RTT